SARomics Biostructures

SARomics Biostructures is a privately held, revenue-generating contract research organization (CRO) specializing in high-end structural biology and early-stage drug discovery services. Founded by experienced scientists, the company has built a recognized global client base across multiple continents by offering integrated services from protein production to fragment screening and lead optimization. Its strategic location near the MAX IV synchrotron provides a competitive advantage in X-ray crystallography throughput and capability. The company operates on a fee-for-service business model, supporting pharmaceutical and biotech clients without developing its own therapeutic pipeline.

Integrated structural biology platform for protein production, characterization, and structure determination. Core techniques include X-ray crystallography (leveraging MAX IV synchrotron) and NMR spectroscopy. Specializes in fragment-based drug discovery using Weak-Affinity Chromatography (WAC), NMR, and crystallographic fragment screening. Offers a FastLane protein-ligand co-crystallization library.

Competes with large, full-service CROs (e.g., Charles River, Evotec) that have structural biology divisions, as well as specialized boutique structural biology firms and academic core facilities. Differentiation is based on deep expertise in fragment-based discovery, rapid turnaround from the FastLane library, and unique access to the MAX IV synchrotron's advanced capabilities.